ArticleFrontiers in molecular biosciences2026
Natural killer cell activated by attenuated newcastle disease virus (NDV) as anti-cancer therapy.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Natural Killer (NK) cells play a central role in innate immunity by targeting virally infected and malignant cells without prior sensitization. However, their activity is often suppressed within the tumor microenvironment. Oncolytic viruses such as Newcastle Disease Virus (NDV) not only selectively replicate in tumor cells but also stimulate immune responses, particularly NK cell activation. Combining attenuated NDV with NK cell therapy may therefore enhance anti-tumor efficacy. Aim: This study aimed to investigate the synergistic anti-cancer potential of NK cells activated by attenuated NDV against breast cancer cell lines AMJ13 and MCF-7, with emphasis on cytotoxicity, adhesion, and immunophenotypic changes. Methods: NK cells were isolated from peripheral blood using separation media and 8 µm mesh filtration, followed by expansion in culture with interleukin-15 (IL-15). Immunofluorescence assays were performed to characterize these NK cells by immunophenotyping through detection of CD3, CD16, Cd56 and CD57 expressions. Co-cytotoxicity was evaluated by WST assay in AMJ13 and MCF-7 cells exposed to NK cells, NDV, or the combination. NK adhesion to tumor cells was assessed by light microscope, scanning electron microscopy (SEM) and immunofluorescence by CD56 detection. Statistical analysis was conducted using GraphPad Prism, and combination effects were analyzed by CompuSyn software. Results: NK cells expanded effectively in IL-15-supplemented culture and displayed enhanced cytotoxicity when combined with NDV, leading to significantly reduced viability in both AMJ13 and MCF-7 cells compared with single treatments (p < 0.05). light and SEM analyses demonstrated NK cell adhesion, morphological alterations, and surface disruption of tumor cells. Immunofluorescence confirmed increased expression of NK marker (CD56) combination in treated groups, supporting functional enhance attachemtn of NK cells. Conclusion: Attenuated NDV significantly augments NK cell-mediated cytotoxicity and adhesion against breast cancer cells. This combinatorial approach offers a promising immunotherapeutic strategy, highlighting the potential of integrating oncolytic virotherapy with NK cell-based therapy for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.